Please assess the completion status of the following clinical trial:

Trial Title: Study of MLN8237 in Combination With Irinotecan and Temozolomide

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Criteria that need to be met to participate in this study:~* Patients must be \> 12 months and \< 30 years of age when registered on study.~* Patients must have relapsed neuroblastoma, refractory neuroblastoma that had less than a partial response to standard treatment or persistent neuroblastoma that had at least a partial response to standard treatment. All patients must have at least ONE site of evaluable disease.~  o Patients who have at least a partial response to standard treatment who still have neuroblastoma that can be seen on CT/MRI or MIBG scans must have a surgical biopsy done of the tumor to confirm that it is neuroblastoma. Patients with relapsed or refractory neuroblastoma do not need to have a biopsy done to enter on study.~* Patients must have adequate heart, kidney, liver and bone marrow function. Patients who have bone marrow disease must still have adequate bone marrow function to enter the study.~* MLN8237 must be swallowed as whole tablets. Therefore, patients must be able to swallow pills to be eligible for study. One tablet is the size of small breath mint, or baby aspirin. Due to the size of MLN8237 tablets, patients must have a body surface area of at least 0.38 m2 to be eligible for study. A body surface area is a combination of a patient's height and weight. An example of a child with a BSA of 0.45 is a child that is 25 inches tall and weighs 25 pounds.You can use the link below to calculate your child's body surface area and determine if they are too small for this trial.~Patients cannot participate in the study if:~* Patients who have received prior MLN8237 are excluded from all phases of the study. Patients previously treated with irinotecan and/or temozolomide will be eligible if they have not had documented progressive disease during treatment with a regimen containing these agents.~* They have other medical problems that could get much worse if they had this treatment.~* They are on dialysis for bad kidney function.~* They are pregnant or breast feeding.~* They have active infections such as hepatitis or fungal infections.~* They have an allergy to treatment with cefixime and cefpodixime.~* They have brain metastasis at study entry, or have received cranial spinal radiation.~* They have had an allogeneic stem cell transplant (received stem cell from someone else).~* They can't cooperate with the special precautions that are needed for this trial.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 30 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.~Irinotecan will be administered intravenously during each course on study day 1 through day 5.~Temozolomide will be administered orally during each course on study day 1 through day 5.

Based on this trial design, predict the completion outcome and termination type (if applicable).